← Leaderboards
James P Ocallaghan
University Of Tennessee Health Sci Ctr
$1,423,674
Attributed
$2,847,347
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $580.8K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,847,347 · 1
By mechanism
R01$2,847,347 · 1
Top collaborators
- Byron C Jones5 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Ann K Cashion$1,548,934
- Byron C Jones$4,970,029
- David George Ashbrook$2,351,681
- Megan Kathleen Mulligan$3,609,287
- Bob Mack Moore$1,121,963
Others in their field
Other Emerging Leaders on “Exposure To”
- Chanza Baytop · Westat, Inc.$271,217,917
- Yunda Huang · Fred Hutchinson Cancer Center$65,418,952
- Prasant Mohapatra · University Of California At Davis$51,108,355
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Leonard Freedman · Leidos Biomedical Research, Inc.$20,851,347
- Kristin Aillon · Midwest Research Institute$18,958,174
Research focus
Exposure ToFamilyEpigenetic ProcessEtiologyAnimal ModelAcetylcholinesterase InhibitorsAcuteBayesian NetworkBioinformaticsAnimal DataBiological MarkersCandidate Disease GeneAnimalsComplexControl LocusCorticosteroneCytokine GeneDesignDiagnosisDissectionDna MethylationBiologicalEnvironmentFluorophosphate
Grant awards (5)
Genetics of epigenetic response to high circulating glucocorticoids and organophosphorus compounds$523,991
R01 · FY2025 · ES
Genetics of epigenetic response to high circulating glucocorticoids and organophosphorus compounds$580,839
R01 · FY2024 · ES
Genetics of epigenetic response to high circulating glucocorticoids and organophosphorus compounds$580,839
R01 · FY2023 · ES
Genetics of epigenetic response to high circulating glucocorticoids and organophosphorus compounds$580,839
R01 · FY2022 · ES
Genetics of epigenetic response to high circulating glucocorticoids and organophosphorus compounds$580,839
R01 · FY2021 · ES